[{"data":1,"prerenderedAt":154},["ShallowReactive",2],{"\u002Fblog\u002Fregulatory-expectations-for-ai-agents-in-gmp":3},{"id":4,"title":5,"author":6,"body":7,"category":134,"date":135,"description":136,"draft":137,"excerpt":138,"extension":139,"heroImage":138,"heroImageAlt":138,"meta":140,"navigation":141,"path":142,"seo":143,"slug":138,"stem":144,"tags":145,"__hash__":153},"blog\u002Fblog\u002Fregulatory-expectations-for-ai-agents-in-gmp.md","Regulatory Expectations for AI Agents in GMP","QikSolve",{"type":8,"value":9,"toc":126},"minimark",[10,18,23,26,29,33,43,49,55,61,67,73,79,85,89,92,99,103],[11,12,13,14],"p",{},"Global regulators now recognise that AI agents and large language models play an active role in\nGxP environments, and their guidance is converging on a consistent principle: ",[15,16,17],"strong",{},"AI agents may\nsupport quality operations, but they cannot replace human accountability.",[19,20,22],"h2",{"id":21},"where-fda-tga-ema-and-mhra-agree","Where FDA, TGA, EMA, and MHRA agree",[11,24,25],{},"Across current guidance, draft annexes, and public statements, regulators are aligned on five core\nprinciples: AI agents constitute a computerised system under GMP; intended use remains the primary\nregulatory anchor; validation prioritises fitness for purpose over model internals; human oversight\nis mandatory for compliance-critical decisions; and traceability and data integrity remain\nnon-negotiable. This consensus appears in FDA draft guidance on AI credibility and risk-based\nvalidation, the draft EU GMP Annex 22 on artificial intelligence, MHRA's participation in\ninternational AI principles and sandbox programmes, and TGA consultation outcomes on software and AI\nin regulated use.",[11,27,28],{},"Regulators do not expect organisations to validate or explain the internal workings of commercial AI\nagents. They do require control over the rationale for AI agent use, the defined tasks it performs,\nits data access parameters, the output review and application process, and the accountability\nframework around it — the same expectations already applied to ERP and QMS platforms.",[19,30,32],{"id":31},"eight-practical-expectations","Eight practical expectations",[11,34,35,38,39],{},[15,36,37],{},"1. Define intended use clearly."," Intended use is the single most important document produced for\nregulatory purposes — it defines the scope of deployment, sets validation boundaries, and\ndetermines the level of human oversight required. A well-formed statement is specific and bounded:\n",[40,41,42],"em",{},"\"AI agents are used to assist with contextual review of GMP records. They do not approve, release,\nor certify data.\"",[11,44,45,48],{},[15,46,47],{},"2. Apply risk-based validation."," Validation depth should match the risk profile of the task.\nRegulators expect scenario-based testing across typical and edge cases, testing with representative\ndata, subject-matter-expert review of outputs, and performance benchmarks against prior methods.\nThey do not require mathematical proof of correctness, access to model weights, or revalidation\nafter every vendor model update.",[11,50,51,54],{},[15,52,53],{},"3. Maintain mandatory human oversight."," Every major agency has stated clearly that AI agents may\ninform, assist, and accelerate quality work, but may not replace qualified human judgement. The\ndistinction is between assistive use, where an agent supports a human decision, and autonomous use,\nwhere an agent makes or finalises a decision without review. Delegating a task to an agent does not\ntransfer regulatory responsibility.",[11,56,57,60],{},[15,58,59],{},"4. Prioritise evidence-based outputs."," An agent output accepted without review, challenge, or\ntraceability is indistinguishable from an undocumented decision — a data integrity risk. Treat all\nagent outputs as working papers, ensure every output is reviewable by a qualified person before it\ninfluences a GMP decision, and ensure all outputs trace back to the source data reviewed.",[11,62,63,66],{},[15,64,65],{},"5. Maintain traceability and data integrity."," Every interaction between an agent and quality data\nshould be captured, timestamped, and linked to a human action, covering input data, timestamp,\nagent output, and human decision — mapping directly to ALCOA+ principles.",[11,68,69,72],{},[15,70,71],{},"6. Apply segregation of duties."," Regulators respond positively to architectures where no single\nagent both performs and approves a task. A two-agent model — one executes, a second independently\nreviews, a human verifies and decides — mirrors the author\u002Freviewer patterns already embedded in\npharmaceutical quality systems.",[11,74,75,78],{},[15,76,77],{},"7. Set explainability expectations pragmatically."," Regulators do not expect explanation of neural\nnetwork internals or reproducibility of individual outputs. They do expect clear documented\ndescriptions of the agent workflow, transparent criteria for evaluating outputs, and honest\nacknowledgement of known limitations.",[11,80,81,84],{},[15,82,83],{},"8. Manage change control and monitoring."," Prompt iterations, workflow adjustments, and data\nsource changes belong inside existing change control. Vendor-managed model updates sit outside\ndirect control, and the risk from those changes is mitigated through human verification, periodic\noutput review, and defined escalation — not by attempting to control what cannot be accessed.",[19,86,88],{"id":87},"preparing-for-inspection","Preparing for inspection",[11,90,91],{},"Auditors typically ask why AI agents are used in a given process, how reliability is validated, who\nverifies outputs, what the contingency is for errors, and whether the organisation can demonstrate a\nconcrete example. They generally avoid probing training methodology, internal algorithmic function,\nor vendor-selection rationale — the focus is on governance, not technical architecture.",[11,93,94,95,98],{},"A regulatory-safe position statement, consistent across FDA, TGA, and EMA\u002FMHRA expectations, reads:\n",[40,96,97],{},"\"We use AI agents as a controlled, assistive tool within our quality system. Human authority drives\nall compliance-critical decisions, ensuring full traceability and oversight.\""," Adopting AI agents\nunder that governance model — retaining full accountability, anchoring use in human oversight, and\nmanaging the governance rather than the technology — is what regulators across jurisdictions are\nconverging on.",[19,100,102],{"id":101},"related-reading","Related reading",[104,105,106,114,120],"ul",{},[107,108,109],"li",{},[110,111,113],"a",{"href":112},"\u002Fblog\u002Foperating-ai-agents-in-gxp-qa-practitioners-guide","Operating AI Agents in GxP: A QA Practitioner's Guide",[107,115,116],{},[110,117,119],{"href":118},"\u002Fblog\u002Ffrom-annex-22-to-agentic-ai-practical-language-for-regulated-ai","From Annex 22 to Agentic AI",[107,121,122],{},[110,123,125],{"href":124},"\u002Fblog\u002Fqxaios-compliance-centric-operating-model-for-ai-systems","QxAIOS: A Compliance-Centric Operating Model for AI Systems",{"title":127,"searchDepth":128,"depth":128,"links":129},"",2,[130,131,132,133],{"id":21,"depth":128,"text":22},{"id":31,"depth":128,"text":32},{"id":87,"depth":128,"text":88},{"id":101,"depth":128,"text":102},"AI Governance","2026-09-10","What FDA, EMA, MHRA, and TGA actually expect of AI agents in GxP — appropriately scoped, risk-based, transparent, human-overseen, and fully traceable.",false,null,"md",{},true,"\u002Fblog\u002Fregulatory-expectations-for-ai-agents-in-gmp",{"title":5,"description":136},"blog\u002Fregulatory-expectations-for-ai-agents-in-gmp",[146,147,148,149,150,151,152],"ai-agents","gmp","fda","ema","mhra","tga","regulatory-compliance","uc0Ctu_pVFioOOYkmtoIamuBo5hftYlgjtP1HJ2nBH0",1789037363358]